Adhesion molecule with Ig-like domain 2 (AMIGO2)

Adhesion molecule with Ig-like domain 2 (AMIGO2) is a transmembrane protein belonging to the immunoglobulin superfamily and characterized by leucine-rich repeats and an Ig-like domain. It mediates both homophilic and heterophilic cell-cell adhesion (interacting with AMIGO1 or AMIGO3) and is essential for the electrical activity-dependent survival of cerebellar granule neurons. AMIGO2 plays a critical role in cancer biology, where it acts as an oncogene by promoting proliferation, migration, adhesion, and metastasis, notably in gastric, colorectal, pancreatic, ovarian, prostate cancers, and melanoma, and is strongly associated with liver metastasis in colorectal cancer. It also regulates immune responses, participating in T-helper cell differentiation and macrophage polarization (M2). AMIGO2 is being investigated as a prognostic biomarker and a potential therapeutic target, with experimental approaches including BET inhibitors and gene silencing being explored for anti-cancer effects. Its expression in neuronal and immune tissues suggests non-trivial challenges regarding therapeutic selectivity and safety.

Other names

Amphoterin-induced protein 2ALI1DEGAAMIGO-2Alivin-1Differentially expressed in gastric adenocarcinomasAmphoterin-induced gene and open reading frame 2Differentially expressed in gastric adenocarcinomaTransmembrane protein AMIGO2

BET inhibitors downregulate AMIGO2 expression, reducing tumor cell proliferation and promoting cell cycle arrest/apoptosis in melanoma (potential, not yet clinical). siRNA targeting AMIGO2 decreases proliferation and invasive behavior in cancer cell lines (experimental). Hypothetical direct antibody or small-molecule antagonists targeting AMIGO2 would inhibit cell adhesion and metastasis (research concept).